US 12,453,743 B2
Mesenchymal stem cell (MSC) growth factor and extracellular vesicle preparation in frozen or powdered form and methods of use
Timothy Alexander Moseley, Fallbrook, CA (US); and Kenneth Allen Pettine, Fort Collins, CO (US)
Assigned to DIRECT BIOLOGICS, LLC, Austin, TX (US)
Appl. No. 17/059,874
Filed by DIRECT BIOLOGICS, LLC, Austin, TX (US)
PCT Filed Apr. 9, 2019, PCT No. PCT/US2019/026595
§ 371(c)(1), (2) Date Nov. 30, 2020,
PCT Pub. No. WO2019/231562, PCT Pub. Date Dec. 5, 2019.
Claims priority of provisional application 62/698,673, filed on Jul. 16, 2018.
Claims priority of provisional application 62/688,012, filed on Jun. 21, 2018.
Claims priority of provisional application 62/681,172, filed on Jun. 6, 2018.
Claims priority of provisional application 62/677,744, filed on May 30, 2018.
Prior Publication US 2021/0196759 A1, Jul. 1, 2021
Int. Cl. A61K 35/28 (2015.01); A61K 38/00 (2006.01); C07K 14/475 (2006.01); C12N 5/0775 (2010.01)
CPC A61K 35/28 (2013.01) [C07K 14/475 (2013.01); C12N 5/0668 (2013.01); A61K 38/00 (2013.01); C12N 2320/30 (2013.01); C12N 2500/02 (2013.01)] 10 Claims
 
1. A pharmaceutical acellular composition for human administration, wherein the pharmaceutical acellular composition comprises:
a therapeutically effective amount of a human bone marrow mesenchymal stem cell (MSC) secretome comprising epidermal growth factor (EGF), bone morphogenetic protein 1 (BMP-1), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and interleukin-6 (IL-6), wherein the therapeutically effective amount is sufficient to reduce inflammation in the human, wherein the pharmaceutical acellular composition is in a powdered form.